GW Pharmaceuticals updates on cannabinoid pipeline

UK biopharma company GW Pharmaceuticals (AIM: GWP) this morning provided an update on the company’s cannabinoid pipeline in the treatment of epilepsy, diabetes and schizophrenia.

“While much of the recent attention regarding GW has been associated with our childhood epilepsy and cancer pain development programs, we continue to make great progress with other pipeline programs, further demonstrating the breadth of our proprietary cannabinoid product development platform to yield interesting and therapeutically beneficial product candidates.” stated Stephen Wright, GW’s director of R&D, adding: “As GW continues to progress its clinical work with cannabinoids, our pipeline has the potential to yield, as it did with Epidiolex, a flow of exciting new product candidates in a wide variety of therapeutic areas.”

GWP42006 (CBDV) for epilepsy